專任研究人員
beckychen@as.edu.tw +886-2-27855696,3090
陳韻晶 研究員
中研院生化所 317室
研究領域與專長
學經歷
主要著作
著作列表

研究領域與專長

本實驗室致力於藥物標靶與精準藥物遞送系統之開發，透過工程化奈米載體設計與分子層級調控，提升核酸、蛋白質、免疫調節分子與小分子藥物在體內的穩定性、專一性與治療效率。我們結合腫瘤生物學、免疫學、化學、生物化學、材料科學與臨床醫學等跨域專長，從基礎生物化學機制出發，聚焦解決實體腫瘤治療中的核心障礙。由於腫瘤常伴隨血管異常、代謝重編程、基質纖維化與免疫抑制等微環境特徵，導致藥物滲透受限與治療抗性產生，我們以「突破腫瘤生物屏障」為核心理念，發展具刺激響應與可控釋放特性的智慧型奈米載體，使其在特定pH值、氧化還原環境或酵素活性條件下精準釋放藥物。透過主動標靶策略，設計高專一性的藥物遞送平台，提升治療劑於腫瘤部位的累積與功能表現，同時降低非特異性副作用。

另一方面，我們聚焦於腫瘤微環境的功能性重塑與免疫調控，透過新型胜肽、LYTAC分子、新型癌症疫苗平台與奈米遞送系統，調節腫瘤代謝途徑與免疫訊息傳導，改變免疫細胞功能，逆轉免疫抑制並克服治療耐受性。最終目標是建構可轉譯、良好生物相容性且可規模化製程的治療平台與標靶分子，並在癌症與纖維化疾病模型中系統性驗證其療效與安全性，建立銜接分子機制研究與臨床應用的創新治療策略。

更多實驗室資訊請見：https://www.yunchinglab.com/

學經歷

  • 2010   Ph.D., Pharmaceutical Sciences, University of North Carolina at Chapel Hill, USA
  • 2004   M.S., Pathology, National Taiwan University
  • 2002   B.S., Biology, National Sun Yat-Sen University
  • 2026 – 迄今   Research Fellow, Institute of Biological Chemistry, Academia Sinica
  • 2020 – 2026   Professor, Institute of Biomedical Engineering, National Tsing Hua University
  • 2016 – 2020   Associate Professor, Institute of Biomedical Engineering, National Tsing Hua University
  • 2013 – 2016   Assistant Professor, Institute of Biomedical Engineering, National Tsing Hua University
  • 2010 – 2013   Postdoctoral Fellow, Harvard Medical School & Massachusetts General Hospital

主要著作

Stimuli-Responsive Nanozyme Reprograms Tumor Immunometabolism and Overcomes Therapeutic Resistance in Hepatocellular Carcinom.
Ta YN, Nguyen VT, Can TT, Hsieh MC, Cao BGT, Wan D, Lai CH, Wu CC, Hsu FF, Yen YT*, Wang SN*, Chen Y*
ACS Nano (2026)

Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.
Nguyen LD, Cheng SL, Yen YT, Lee HM, Wu TH, Wang J*, Lin SY*, Chen Y*
Advanced Science (2025)

Polyethylene glycol immunogenicity in nanomedicine.
Chen Y, Su YC, Roffler SR*
Nature Reviews Bioengineering (2025)

Robust and Sustained STING Pathway Activation via Hydrogel-Based In Situ Vaccination for Cancer Immunotherapy.
Cheng SL, Lee HM, Li CP, Lin MW, Chou MY, Yen YT, Wu TH, Lian YC, Shih YC, Chiang CS, Chen TW*, Wan D*, Chen Y*
ACS Nano (2024)

A Chemoimmunotherapy Nanogel Enables Efficient Delivery of Interleukin-2 and Induction of Immunogenic Cell Death for Effective Cancer Therapy.
Mu HY, Ta YN, Tham MJR, Hsu FF, Lin YC, Huang HC, Sung YC, Huang CI, Wu CL, Chang CH, Yang S, Lee TY, Wan D, Wang J, Duda DG, Boucher Y, Huang JH*, Ang WH*, Chen Y*
Advanced Functional Materials (2024)

Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC, Sung YC, Li CP, Wan D, Chao PH, Tseng YT, Liao BW, Cheng HT, Hsu FF, Huang CC, Chen YT, Liao YH, Hsieh HT, Shih YC, Liu IJ, Wu HC, Lu TT*, Wang J*, Chen Y*
Gut (2022)

A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Song JS, Chang CC, Wu CH, Dinh TK, Jan JJ, Huang KW, Chou MC, Shiue TY, Yeh KC, Ke YY, Yeh TK, Ta YN, Lee CJ, Huang JK, Sung YC, Shia KS*, Chen Y*
Proc. Natl. Acad. Sci. U.S.A (2021)

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, Lin CY, Lin YC, Chang PC, Lin SY*, Chen Y*
Science Advances (2020)

Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies.
Sung YC, Jin PR, Chu LA, Hsu FF, Wang MR, Chang CC, Chiou SJ, Qiu JT, Gao DY, Lin CC, Chen YS, Hsu YC, Wang J, Wang FN, Yu PL, Chiang AS, Wu AY, Ko JJ, Lai CP, Lu TT*, Chen Y*
Nature Nanotechnology (2019)

著作列表